NCT02533011

Brief Summary

Present criteria used to define sepsis are non-specific, making it difficult to both distinguish sepsis from other diseases and to predict which patients are likely to become more severely ill. In standard care, patients at risk of becoming more severely ill are neither identified nor indicated for resuscitative efforts until they develop hemodynamic insufficiency or organ failure; after progression to severe disease, mortality increases significantly. The identification of risk patients can lead to earlier initiation of resuscitation therapies and potentially lead to reduced morbidity and mortality. This study aims to determine whether Heparin-binding protein (HBP), which is secreted from neutrophils during infection and a mediator of vascular leakage, can act as a biomarker for the progression to severe sepsis with circulatory failure. The objective of this study is to validate the utility of HBP to predict the development of delayed onset organ dysfunction in sepsis in patients and to compare the performance of HBP relative to currently used prognostic biomarkers in sepsis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,055

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

July 16, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 26, 2015

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
Last Updated

September 25, 2017

Status Verified

September 1, 2017

Enrollment Period

1.4 years

First QC Date

July 16, 2015

Last Update Submit

September 22, 2017

Conditions

Keywords

SepsisHeparin Binding Protein

Outcome Measures

Primary Outcomes (1)

  • Infection with organ dysfunction, defined as PIRO (Predisposition, Insult, Response, Organ Dysfunction) Score greater than 5

    Patients with septic shock or severe sepsis

    72 hours after meeting sepsis criteria

Study Arms (3)

24 Hours

HBP lab test performed 24 hours after meeting sepsis inclusion criteria.

Other: HBP lab test

48 Hours

HBP lab test performed 48 hours after meeting sepsis inclusion criteria.

Other: HBP lab test

72 Hours

HBP lab test performed 72 hours after meeting sepsis inclusion criteria.

Other: HBP lab test

Interventions

Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.

Also known as: Plasma level of heparin binding protein
24 Hours48 Hours72 Hours

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients admitted through the emergency department with infection.

You may qualify if:

  • Clinical diagnosis of a bacterial or viral infection
  • years or older
  • Meet the sepsis alert criterion (Hypotension (BP \< 90 after 2 L of fluids or lactate ≥ 4) OR
  • PIRO (Predispose, Infection, Response, Organ dysfunction ) score ≥ 15 .

You may not qualify if:

  • Minors (less than 18 years of age)
  • Patients who do not meet sepsis criteria as described above

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Christiana Care Health System

Newark, Delaware, 19718, United States

Location

Related Publications (22)

  • Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest. 2006 Apr;129(4):968-78. doi: 10.1378/chest.129.4.968.

    PMID: 16608946BACKGROUND
  • Shapiro N, Howell MD, Bates DW, Angus DC, Ngo L, Talmor D. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med. 2006 Nov;48(5):583-90, 590.e1. doi: 10.1016/j.annemergmed.2006.07.007.

    PMID: 17052559BACKGROUND
  • Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013 Mar 2;381(9868):774-5. doi: 10.1016/S0140-6736(12)61815-7. No abstract available.

    PMID: 23472921BACKGROUND
  • Glickman SW, Cairns CB, Otero RM, Woods CW, Tsalik EL, Langley RJ, van Velkinburgh JC, Park LP, Glickman LT, Fowler VG Jr, Kingsmore SF, Rivers EP. Disease progression in hemodynamically stable patients presenting to the emergency department with sepsis. Acad Emerg Med. 2010 Apr;17(4):383-90. doi: 10.1111/j.1553-2712.2010.00664.x.

    PMID: 20370777BACKGROUND
  • Arnold RC, Sherwin R, Shapiro NI, O'Connor JL, Glaspey L, Singh S, Medado P, Trzeciak S, Jones AE; Emergency Medicine Shock Research Network (EM Shock Net) Investigators. Multicenter observational study of the development of progressive organ dysfunction and therapeutic interventions in normotensive sepsis patients in the emergency department. Acad Emerg Med. 2013 May;20(5):433-40. doi: 10.1111/acem.12137.

    PMID: 23672356BACKGROUND
  • Bastani A, Galens S, Rocchini A, Walch R, Shaqiri B, Palomba K, Milewski AM, Falzarano A, Loch D, Anderson W. ED identification of patients with severe sepsis/septic shock decreases mortality in a community hospital. Am J Emerg Med. 2012 Oct;30(8):1561-6. doi: 10.1016/j.ajem.2011.09.029. Epub 2011 Dec 26.

    PMID: 22204997BACKGROUND
  • Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589-96. doi: 10.1097/01.CCM.0000217961.75225.E9.

    PMID: 16625125BACKGROUND
  • Rivers EP, Katranji M, Jaehne KA, Brown S, Abou Dagher G, Cannon C, Coba V. Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiol. 2012 Jun;78(6):712-24. Epub 2012 Mar 23.

    PMID: 22447123BACKGROUND
  • Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC; GenIMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1242-7. doi: 10.1164/rccm.200712-1777OC. Epub 2008 Mar 27.

    PMID: 18369199BACKGROUND
  • Cuthbertson BH, Elders A, Hall S, Taylor J, MacLennan G, Mackirdy F, Mackenzie SJ; Scottish Critical Care Trials Group; Scottish Intensive Care Society Audit Group. Mortality and quality of life in the five years after severe sepsis. Crit Care. 2013 Apr 16;17(2):R70. doi: 10.1186/cc12616.

    PMID: 23587132BACKGROUND
  • Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, Angus DC, Kellum JA; Genetic and Inflammatory Markers of Sepsis (GenIMS) Investigators. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 2010 Mar;77(6):527-35. doi: 10.1038/ki.2009.502. Epub 2009 Dec 23.

    PMID: 20032961BACKGROUND
  • Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH. Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med. 2014 May 1;189(9):1075-81. doi: 10.1164/rccm.201311-2097OC.

    PMID: 24601781BACKGROUND
  • Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, Norrby-Teglund A, Flodgaard H, Lindbom L, Bjorck L. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell. 2004 Feb 6;116(3):367-79. doi: 10.1016/s0092-8674(04)00057-1.

    PMID: 15016372BACKGROUND
  • McNamara C, Zinkernagel AS, Macheboeuf P, Cunningham MW, Nizet V, Ghosh P. Coiled-coil irregularities and instabilities in group A Streptococcus M1 are required for virulence. Science. 2008 Mar 7;319(5868):1405-8. doi: 10.1126/science.1154470.

    PMID: 18323455BACKGROUND
  • Macheboeuf P, Buffalo C, Fu CY, Zinkernagel AS, Cole JN, Johnson JE, Nizet V, Ghosh P. Streptococcal M1 protein constructs a pathological host fibrinogen network. Nature. 2011 Apr 7;472(7341):64-8. doi: 10.1038/nature09967.

    PMID: 21475196BACKGROUND
  • Linder A, Akesson P, Brink M, Studahl M, Bjorck L, Christensson B. Heparin-binding protein: a diagnostic marker of acute bacterial meningitis. Crit Care Med. 2011 Apr;39(4):812-7. doi: 10.1097/CCM.0b013e318206c396.

    PMID: 21200320BACKGROUND
  • Kjolvmark C, Akesson P, Linder A. Elevated urine levels of heparin-binding protein in children with urinary tract infection. Pediatr Nephrol. 2012 Aug;27(8):1301-8. doi: 10.1007/s00467-012-2132-x. Epub 2012 Mar 13.

    PMID: 22410798BACKGROUND
  • Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55. doi: 10.1378/chest.101.6.1644.

    PMID: 1303622BACKGROUND
  • Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Apr;31(4):1250-6. doi: 10.1097/01.CCM.0000050454.01978.3B.

    PMID: 12682500BACKGROUND
  • Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 Feb;39(2):165-228. doi: 10.1007/s00134-012-2769-8. Epub 2013 Jan 30.

    PMID: 23361625BACKGROUND
  • Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, Moretti E, Nguyen HB, Gunnerson KJ, Milzman D, Gaieski DF, Goyal M, Cairns CB, Ngo L, Rivers EP. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med. 2009 Jan;37(1):96-104. doi: 10.1097/CCM.0b013e318192fd9d.

    PMID: 19050610BACKGROUND
  • Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012 Oct;25(4):609-34. doi: 10.1128/CMR.00016-12.

    PMID: 23034322BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample

MeSH Terms

Conditions

SepsisInfectionsShock, Septic

Condition Hierarchy (Ancestors)

Systemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Study Officials

  • Ryan C. Arnold, MD

    Christiana Care Health Services

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 16, 2015

First Posted

August 26, 2015

Study Start

July 1, 2015

Primary Completion

December 1, 2016

Study Completion

July 1, 2017

Last Updated

September 25, 2017

Record last verified: 2017-09

Locations